FDA signs off on Sanofi's insulin biosimilar, the first for Novo Nordisk's rapid-acting NovoLog
The FDA has given a thumbs up to Sanofi’s Merilog as the first biosimilar substitute for Novo Nordisk’s NovoLog for patients with diabetes. It is delivered by a subcutaneous shot 5 to 10 minutes before mealtime to help patients manage glucose and limit blood sugar spikes.
The FDA has given a thumbs up to Sanofi’s Merilog as the first biosimilar substitute for Novo Nordisk’s NovoLog for patients with diabetes. It is delivered by a subcutaneous shot 5 to 10 minutes before mealtime to help patients manage glucose and limit blood sugar spikes.
